50 Participants Needed

Palliative Care Information for Multiple Sclerosis

Recruiting at 1 trial location
AB
Overseen ByAliza Ben-Zacharia, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Hunter College of City University of New York
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study is using a central, computer-generated simple randomization technique. Participants will be randomly assigned to groups within the constraints of ensuring balanced representation of gender, ethnicity, and race. One-half of the patients are randomized to the decision aid video model, and one-half will serve as controls and receive a palliative care (PC) informational sheet. Sessions are designed to be consistent with PC principles of care using constructs from the Murray's transition theory including knowledge development coupled with advanced care planning (ACP)-to drive palliative care alongside curative treatment, and to support people with chronic progressive illnesses. The 2 groups will complete the demographic forms, and pre- and post-tests, at baseline and after three months. The intervention group will view the video decision aid, which takes 10 minutes, during their follow up appointment. The controls will read written information of the same content shown on the video and will complete similar questionnaires. The video opens with empathic statements regarding the situation in which patients may find themselves, including an introduction about medical decisions, and statements regarding values and spiritual beliefs and their impact on decision-making. The video translates the information into actionable medical orders using a three-goal framework: life-prolonging care, limited/blended care, and comfort care. The video describes the features of each of the goals of care and the risks and benefits of each option using visual images that illustrate the interventions. Patients will review the video using iPads and will be able to review the video again as needed. The Flesch-Kincaid ease score for the video narration is 71.6; for the "Conversation" piece, it is 65.9. These indicate that the passages require approximately a 7th or 8th grade reading level, which Flesch suggests makes them "easy to read" and "plain English," respectively. The goal of the video intervention is to help patients express their values and health goals, while achieving their life and core values. The intervention group will view the video which includes modules to teach patients strategies for expressing their concerns and enhance their self-efficacy, helping them overcome any barriers. To enhance intervention fidelity, an ACP facilitator guide will be developed as reference for the intervention implementation. It will detail the key topics and purposes of each session of the intervention, the guiding questions, and the facilitation skills. Aim 1: To explore the preferences of patients with neuroinflammatory diseases, PC knowledge, decisional conflict, and preparation for decision making among 50 adult (18-65 years old) patients randomly assigned to one of two PC modalities: 1. a video depicting PC goals of care (intervention group, n=25), or 2. standard usual care using PC written information (control group, n=25). H1a: Patients randomized to the video will have higher documented preferences and fewer preferences for life-prolonging interventions (primary outcome) than the control group. The intervention group will have greater knowledge, lower decisional conflict, and greater preparation for decision making than those randomized to the control group. Aim 2: To compare PC conversations and documentation at 3 months among patients with neuroinflammatory diseases. H2: Patients randomized to the video will have more PC conversations and higher rates of PC documentation after 3 months.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on providing information and support for decision-making in palliative care, so it's unlikely that medication changes are required.

What data supports the effectiveness of the treatment Palliative Care Model for Multiple Sclerosis?

Preliminary evidence suggests that palliative care may be beneficial for people with severe multiple sclerosis, as it addresses complex physical and emotional needs. A pilot study also indicates that patients and caregivers can benefit from palliative care services, such as counseling hotlines, which help connect them to necessary support.12345

How does the Palliative Care Model treatment differ from other treatments for multiple sclerosis?

The Palliative Care Model for multiple sclerosis focuses on improving quality of life through symptom management, psychosocial support, and rehabilitation, rather than trying to prevent or delay disease progression. This approach is unique because it addresses the complex physical and emotional needs of patients with severe, progressive MS, which are often not the primary focus of standard disease-modifying treatments.23456

Eligibility Criteria

This trial is for adults aged 18-65 with neuroinflammatory diseases like Multiple Sclerosis. Participants should be able to understand content at a 7th or 8th grade reading level. The study aims to include a balanced representation of gender, ethnicity, and race.

Inclusion Criteria

Speak English since all instruments are available in English
I was diagnosed with MS, NMOSD, or anti-MOG over 2 years ago.
I am between 18 and 65 years old.

Exclusion Criteria

Visually impaired (note, hearing impaired is not an exclusion criterion as the video is closed captioned)
Psychological state not appropriate for PC discussions as determined by the Patient Health Questionnaire 9 (PHQ9)
A score of 11 or higher, indicative of major depressive disorder, will be referred to immediate management and excluded from the study
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants complete demographic forms and pre-tests

1 week
1 visit (in-person)

Intervention

Participants are randomized to either view a palliative care video or read written information, followed by post-tests

1 week
1 visit (in-person)

Follow-up

Participants are contacted by telephone to reassess goals-of-care preferences and complete post-tests

3 months
1 visit (virtual)

Treatment Details

Interventions

  • Palliative Care Model
Trial OverviewThe trial tests two methods of delivering palliative care information: one group watches a video decision aid about goals of care, while the control group reads written material on the same topic. Both groups fill out questionnaires before and after three months.
Participant Groups
2Treatment groups
Active Control
Group I: Control armActive Control1 Intervention
The control arm will follow standard of care which comprises palliative care (PC)written material about the PC conversation and advance directives.
Group II: Intervention groupActive Control1 Intervention
The intervention group wil view a palliative care (PC) video discussing the PC conservation and advanced care planning (ACP).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hunter College of City University of New York

Lead Sponsor

Trials
43
Recruited
10,000+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials
394
Recruited
404,000+

Findings from Research

A home-based palliative approach (HPA) for adults with severe multiple sclerosis (MS) was found to significantly reduce symptom burden compared to usual care, with effect sizes of 0.20 at 3 months and 0.32 at 6 months based on the Palliative care Outcome Scale-Symptoms-MS.
However, the HPA did not show a significant impact on the quality of life or other secondary outcomes for patients and their carers, indicating that while symptom relief was achieved, overall quality of life improvements were not evident.
Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.Solari, A., Giordano, A., Patti, F., et al.[2019]
A pilot palliative care counseling hotline for severely affected multiple sclerosis patients received 18 calls in its first year, with 10 callers qualifying for palliative care services based on their medical and caregiving needs.
The study indicates that the hotline is a valuable resource for connecting patients and caregivers to palliative care, and plans are in place to expand the service nationwide to better support more individuals in need.
A palliative care hotline for multiple sclerosis: A pilot feasibility study.Knies, AK., Golla, H., Strupp, J., et al.[2018]
The guideline developed for palliative care in patients with severe, progressive multiple sclerosis (MS) includes 34 recommendations, emphasizing the need for home-based palliative care to address the complex needs of these patients.
There is a significant lack of evidence regarding effective interventions for symptom management and caregiver support in this population, highlighting the need for further research in these areas.
EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis.Solari, A., Giordano, A., Sastre-Garriga, J., et al.[2023]

References

Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. [2019]
A palliative care hotline for multiple sclerosis: A pilot feasibility study. [2018]
EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. [2023]
Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. [2018]
EAN guideline on palliative care of people with severe, progressive multiple sclerosis. [2021]
Palliative care in patients with multiple sclerosis. [2019]